Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9697620 | 0.93 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL9699972 | 0.84 | — | — | |
| SCHEMBL25101310 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL15423501 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL19447773 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL21256200 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL7890530 | 0.77 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL2370323 | 0.77 | MAOB (0.32) | MAOB | |
| SCHEMBL17743232 | 0.76 | — | — | |
| SCHEMBL9850853 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230019236-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2022015977-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| US-10851073-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | ABBVIE INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200317644-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2020-10-08 | — | — | US | disclosed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| EP-3524599-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2019-08-14 | — | — | EP | disclosed |
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | CELLUMEN INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | CELLUMEN INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | MERCK FROSST CANADA LTD. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2009-03-19 | — | — | US | disclosed |
| US-7442716-B2 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2007-09-06 | — | — | US | disclosed |
| EP-0518636-A1 | Liquid crystal compounds and compositions | SANYO CHEMICAL INDUSTRIES LTD. (JP) | 1992-12-16 | — | — | EP | disclosed |
| EP-0517498-A1 | Liquid crystal compounds and compositions | SANYO CHEMICAL INDUSTRIES LTD. (JP) | 1992-12-09 | — | — | EP | disclosed |
| EP-0500210-A2 | Liquid crystal compounds and compositions | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 1992-08-26 | — | — | EP | disclosed |
| EP-0409634-A2 | Liquid crystal compounds and optically active compounds | SANYO CHEMICAL INDUSTRIES LTD. (JP) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | ALDH1A1 1981/4885MAOB 4500/4885LMNA 1922/4885 |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | ALDH1A1 1200/4885MAOB 1221/4885LMNA 4349/4885 |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALDH1A1 4654/4885MAOB 3568/4885LMNA 2339/4885 |
| US-20230019236-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | ALDH1A1 3671/4885MAOB 2577/4885LMNA 4811/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | ALDH1A1 1981/4885MAOB 4500/4885LMNA 1922/4885 |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | GSTO1, PTGS1, PTGES | ALDH1A1 78/4885MAOB 332/4885LMNA 947/4885 |
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | PTGES, PTGS1, PTGES2 | ALDH1A1 158/4885MAOB 742/4885LMNA 3717/4885 |
| US-10851073-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PTPN1, PTPN2, PTPN18 | ALDH1A1 3671/4885MAOB 2577/4885LMNA 4811/4885 |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | ALDH1A1 165/4885MAOB 635/4885LMNA 4356/4885 |
| US-20200317644-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | ALDH1A1 1200/4885MAOB 1221/4885LMNA 4349/4885 |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | ALDH1A1 165/4885MAOB 635/4885LMNA 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.